CHA Bio Group is a global leader in the field of cell and gene therapy, focusing on the development of innovative treatments for rare cancers and intractable diseases. The company possesses advanced technologies for the selection of optimal cell lines tailored to specific diseases, enabling the creation of personalized cell therapies. Additionally, CHA Bio Group has established itself as a significant player in the stem cell sector, holding a notable number of global patents, ranking fourth worldwide. Their commitment to research and development is evident in their efforts to accelerate R&D initiatives and achieve new business milestones.

The company also operates a comprehensive contract development and manufacturing organization (CDMO) that specializes in the full-cycle GMP production and testing of advanced biopharmaceuticals, including cell and gene therapies. CHA Bio Group's capabilities extend to the storage of stem cells and immune cells, offering advanced regenerative medical solutions aimed at anti-aging and overcoming difficult diseases. Furthermore, they leverage IT expertise to develop digital healthcare services and platforms, integrating AI and big data technologies to enhance medical information systems and improve healthcare delivery.

South Korea

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. 
We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform.
We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CHA Bio Group

Company Details